Problem

Healthcare and life-sciences organizations struggle to extract usable intelligence from fragmented, unstructured clinical data. Patient information is spread across multiple electronic medical records and health networks, while clinicians and researchers lack a shared language: manually reviewing one chart can take 45 minutes to several hours, and scaling that work across hundreds of thousands of patients is impractical. Mendel’s economic value proposition is to reduce this bottleneck, with the company claiming that its technology can unlock 80% of medical data and perform abstraction 27,000 times faster than manual methods.

The clearest high-value use case is clinical-trial recruitment, particularly oncology cohort matching and prescreening. Finding eligible patients requires interpreting nuanced diagnoses, treatments, and longitudinal histories; Mendel aims to make that process faster and more accurate, while also supporting real-world evidence, treatment analysis, prior authorization, and precision-medicine workflows.

Product / Service

Mendel is an enterprise clinical-AI platform that indexes structured and unstructured records and lets healthcare workers query patient data in natural language. Its HyperCube product unifies clinical data and supports semantic search, while Resolve creates a consolidated longitudinal view of the patient. The platform also offers workflow-specific AI co-pilots for file matching, prior authorization, and abstraction, with customers able to build their own co-pilots.

Technically, Mendel combines large language models with a proprietary clinical hypergraph and neuro-symbolic reasoning rather than relying on an LLM alone. Its stack includes document processing, OCR, classification, entity and relationship extraction, de-identification, and retrieval and generation. The intended benefit is clinician-like reasoning at machine scale with more controllable, explainable, and consistent outputs; in a 2024 benchmark involving 1,400 patient records, Mendel reported outperforming GPT-4 for automatic cohort retrieval.

Market

Mendel competes in clinical AI, healthcare natural-language processing, real-world evidence, and clinical-data infrastructure for providers, biopharma, diagnostics companies, and other life-sciences organizations. Directly comparable companies identified in the research include COTA, Autonomize, and Pentavere; the broader competitive set also includes ConcertAI, Saama Technologies, Verantos, ScienceIO, and Vasta Global. Its differentiation is the combination of clinical data extraction, longitudinal patient views, and hypergraph-based reasoning for research and care workflows.

The available evidence indicates that Mendel is an operating, commercially oriented company rather than a pre-revenue project. AWS described leading life-sciences companies as clients, and the company has publicly documented a $40 million Series B led by Oak HC/FT and $65 million raised in total as of April 2022. It also reported a Databricks partnership that unified data and ETL pipelines and accelerated model training, while clinical-trial studies and collaborations with Cornell University and the University of Pennsylvania provide evidence of product validation. The evidence does not establish audited revenue or a definitive 2026 revenue figure.